Anal Cancer Market
May 23, 2025
Incyte’s Zynyz Secures Approval for Anal Cancer—A Comeback After FDA Rejection
Following two simultaneous FDA approvals, Incyte’s PD-1 inhibitor Zynyz has made a comeback in the treatment of anal cancer, four years after being initially rejected by the agency. On May 15, 2025, Incyte announced that the FDA approved Zynyz (retifanlimab-dlwr), a humanized monoclonal antibody that targets the PD...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
